So does that mean ACE inhibitors increase risk of complications/more severe illness in Covid-19? Or the opposite? I don't understand at all
Do we have reliable evidence showing that IFNs are elevsted in ME?
I think we don't know if ACE inhibitors increase or decrease infection/severity yet. As far as I understand(I may be wrong), he is saying that IFNy and IFNa do increase risk. That's why I'm wondering if we have elevated levels or not.So does that mean ACE inhibitors increase risk of complications/more severe illness in Covid-19? Or the opposite? I don't understand at all![]()
Yes, I've actually been looking for that in the past couple of days but it seems that there is no study that does this.So co-morbidities are hugely important. Would be good to analyse the interaction of age and co-morbidities (there was no data on that).
So, if it would turn out that cases and deaths are elevated in countries with a lot of sugar consumption, this could be an explanation, couldn´t it?
... Sugars are made from fat in the body if sugar intake is less.
... Most of the sugars in glycoproteins are not glucose - e.g mannose, galactose, n-acetyl glucosamine, sialic acid.
Just found a study that puts comorbditiy and age in a multivariable regession. https://www.unboundmedicine.com/med..._of_patients_with_COVID_19_in_Shanghai_China_it seems that there is no study that does this.
As you can see from the data there seems to be a very strong relationship between age and case fatality rate. So perhaps this could explain the connection between comorbidities and CFR: perhaps age is the main driver behind this correlation. That might explain why pretty much all comorbidities seem to result in a large increase in case fatality rates. If comorbidity was the main factor I would expect to see more differentiation between for example cancer and chronic respiratory disease on the one hand and diabetes and hypertension on the other. You might think the former is more of a risk factor for COVID-19 than the latter as many persons with diabetes and/or hypertension experience relatively few disabilities and symptoms that aren't directly related to respiratory distress.
Unlike common viral agents (such as Adenovirus, Rhinovirus, Norovirus, Influenza, Respiratory Syncytial Virus), Coronaviruses have not shown to cause a more severe disease in immunosuppressed patients. For this family of viruses the host innate immune response appears the main driver of
lung tissue damage during infection. More importantly, reviewing the mortality and morbidity reports published on Coronaviruses outbreaks such as Severe Acute Respiratory Syndrome (SARS) that emerged in 2002, Middle East Respiratory Syndrome (MERS, still ongoing) and more recently COVID-19, no fatality was reported in patients undergoing transplantation, chemotherapy or other immunosuppressive treatments, at any age. Risk factors for poor outcome include advanced age, male sex and presence of comorbidities (obesity, diabetes, heart disease, lung disease, kidney disease). The Hospital Papa Giovanni XXIII in Bergamo, is located in the “red zone” of the Italian outbreak, and hosts the main paediatric hepatology and liver transplantation centre of Italy. Our preliminary experience, in agreement with recent data from China, shows that, among patients in the follow-up for cirrhosis, transplantation, autoimmune liver disease, chemotherapy for hepatoblastoma, none developed a clinical pulmonary disease, despite some tested positive for SARS-CoV-2.
My cognitive function stamina is short and I’m stressed and confused - I could really do with some help.